Neoadjuvant HER2+

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Disitamab vedotin alone and with ICIs, TKIs, or other antiangiogenic agents had consistent efficacy in patients with HER2-positive or -low breast cancers.

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

Maria Hafez, MD, explains how hormone receptor status, risk stratification, & other factors influence clinical decisions in early HER2+ breast cancer.

Nina D'Abreo, MD, discusses advances made in the treatment of patients with HER2-low and HER2-positive breast cancers.

Maria Hafez, MD, spotlights the KATHERINE trial in HER2-positive breast cancer, expanding on the respective toxicity profiles of T-DM1 and trastuzumab that were identified in an exploratory safety analysis of the trial; updated outcomes with T-DM1 in those with residual invasive disease after neoadjuvant treatment and surgery; and more.

The novel bispecific antibody KN026 and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive early or locally advanced breast cancer.

Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.

Javier Cortés, MD, PhD, expands on the importance of investigating the central nervous system activity of trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases; key efficacy data from the pooled analysis of the agent in the DESTINY-Breast01, -02 and -03 trials; and more.